Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid TumorsBusiness Wire • 12/29/21
Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer PatientBenzinga • 12/20/21
CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher TodayInvestorPlace • 12/20/21
Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II StudyBusiness Wire • 12/20/21
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022Benzinga • 12/07/21
Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022Business Wire • 12/07/21
Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical UpdatesBenzinga • 11/26/21
Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical UpdateBusiness Wire • 11/26/21
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021Business Wire • 11/24/21
Can-Fite's Piclidenoson Commences Clinical Study for the Treatment of Canine OsteoarthritisBusiness Wire • 11/23/21
Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting® 2021 ConferenceBusiness Wire • 11/01/21
Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development SummitBusiness Wire • 10/26/21
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific JournalBenzinga • 10/21/21
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal.Business Wire • 10/21/21
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021Business Wire • 10/05/21